Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

up study, patients completing both initial studies are to be given Cimzia(R) every four weeks for up to seven years. In the second follow-up study, patients who relapsed in either initial study (defined as an increase in CDAI of >70 or absolute CDAI of >350) were re-introduced to Cimzia(R) every four weeks to be continued for up to seven years, with a single additional dose at week 2.

About Crohn's Disease

Crohn's disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). If not effectively treated, it results in the need for surgery. Crohn's disease has been estimated to affect as many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD).

About Cimzia(R) (certolizumab pegol)

Cimzia(R) is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia(R) in Crohn's disease, rheumatoid arthritis and other autoimmune disease indications. Cimzia(R) is a registered trademark of UCB Inc. For full prescribing information, please visit http://www.Cimzia.com.

IMPORTANT SAFETY INFORMATION

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have bee
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2,500 scientists and experts from around the world will ... for the largest international meeting of the year devoted ... fields as far flung as genomics and geology who ... processes to creating life-saving drugs. This meeting ... has declared 2014 the International Year of Crystallography (IYCr2014) ...
(Date:7/28/2014)... Va. , July 28, 2014  Serco ... services, announced the Company has been awarded a ... Support Command (NEMSCOM) and its Deployable Medical Systems.  ... enable medical personnel to provide world-class healthcare to ... operating environment across the globe. The five year ...
(Date:7/28/2014)...  UBM Medica US announces that Diagnostic ... imaging professionals, explored the complex situation regarding measuring ... The shift from fee-for-service has left radiology at ... is determined in the new payment model . ... field, who recognized the complexity of the radiologist,s value: ...
Breaking Medicine Technology:All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 2All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 3All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 4All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 5All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... ... today that new data, including a late-breaking presentation on Tasigna® ... leukemia, demonstrate the strength of the company,s hematology portfolio in ... at the 51st American Society of Hematology (ASH) Annual Meeting ...
... 1 Patient Safety Technologies, Inc. (OTC Bulletin Board: ... Rose, CPA(PA), to the position of Chief Financial Officer, ... has been acting CFO since 2008. Prior to ... President Finance, Chief Financial Officer, Treasurer and Corporate Secretary ...
Cached Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... July 28, 2014 The Oakwood Foundation ... Birkhill, Wang, Songe and Associates, PC that will benefit ... tomorrows to come. , The HBWS group is ... more than $2.5 million in donations. Through their latest ... for the Oakwood Women’s Healthcare Classic for the next ...
(Date:7/28/2014)... regions in the brain was able to arouse animals ... In the August issue of Anesthesiology , investigators ... with continuous doses of either agent would move, raise ... electrical stimulation delivered to the ventral tegmental area (VTA). ... substantia nigra, did not induce the animals to wake ...
(Date:7/28/2014)... The report, “Blowing Agents Market by Type, ... Forecasts to 2019” defines and segments the global ... the global consumption volume and value. , Browse ... figures spread through 226 Pages and in-depth TOC ... Blowing agents are highly utilized materials as a ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... plans are partnering with physician practices to initiate a range ... these programs have resulted in decreased emergency room (ER) use, ... by the Alliance of Community Health Plans (ACHP), are part ... way community health plans partner with providers to improve care. ...
... Risk Factors for,Developing MS, UB Study Shows, ... insufficiency (CCSVI), which has attracted global attention as possibly being ... for the presence of risk factors in subjects who do ... study of 252 volunteers has found an association between CCSVI ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) ... drink or doing some last-minute grooming, a large majority of ... distracted while behind the wheel, a new poll shows. ... adults who drive on a regular basis admitted to having ...
... health care workers at risk of 2009 H1N1 infection during ... according to a study published in the December issue of ... the Society of Healthcare Epidemiology of America. ... Prevention (CDC), tracked 63 Southern California health care workers who ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women ... those with other forms of breast cancer to have a ... finds. Swedish researchers examined the family history, pathology reports ... 1980 and 2008. About 40 percent of the women had ...
... About 40 percent of young adults who,ve attempted suicide made ... thoughts and behavior may begin much younger than previously believed, ... ongoing survey, University of Washington researchers asked almost 900 young ... attempts. Nearly 9 percent (78) of the participants said ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: